YOLFTbeta
Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

ATRA · NASDAQ · Healthcare / Biotechnology

7.70USD-0.23 (-2.90%)

Price History

Full chart

Market Stats

Previous Close7.93
Open7.63
Day Range7.46 – 7.80
52-Week Range3.92 – 19.15
Volume17.03K
Market Cap85.72M
P/E (TTM)0.00
Forward P/E16.16
EPS-1.54
Dividend Yield0.00%
Beta0.11
50-Day Avg8.94
200-Day Avg8.54

About

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Anhco Nguyen Ph.D.
  • Employees10
  • Headquarters1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320, USA
  • Websitehttps://www.atarabio.com

Leadership

  • Dr. Anhco Nguyen Ph.D.President, CEO & Director · b. 1973
  • Mr. Kevin G. Sarney CPAInterim Chief Financial Officer · b. 1965
  • Mr. Jim SesicSenior Vice President of Regulatory Affairs

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0000003.55M20.34M63.57M8.57M128.94M120.77M
Growth (%)---------+472.64%+212.55%-86.51%+1404.02%-6.33%
Cost of Revenue--048.00K383.00K956.00K3.78M8.11M9.87M11.38M269.99M8.89M21.01M21.21M
Gross Profit--0-48.00K-383.00K-956.00K-3.78M-8.11M-9.87M20.34M-206.42M-313.00K107.93M99.56M
Gross Margin---------277.79%100.00%-324.69%-3.65%83.71%82.44%
Operating Expense--28.16M58.40M80.86M120.58M233.33M287.58M299.19M360.80M74.10M275.69M191.37M63.70M
Operating Income-3.23M-8.62M-28.16M-58.45M-81.24M-121.53M-237.11M-295.68M-309.05M-340.46M-280.51M-276.01M-83.44M35.86M
Operating Margin---------8700.79%-1673.85%-441.25%-3219.48%-64.71%29.69%
EBITDA-4.09M-8.61M-28.15M-58.40M-80.86M-120.58M-233.38M-288.61M-300.72M-331.12M-222.26M-266.00M-75.75M38.63M
EBITDA Margin---------8466.22%-1627.91%-349.62%-3102.73%-58.75%31.98%
Net Income-123.30M-87.73M-28.01M-57.22M-79.05M-119.49M-230.70M-290.98M-306.62M-340.14M-228.30M-276.13M-85.40M32.69M
Net Income Margin---------8632.32%-1672.28%-359.12%-3220.88%-66.23%27.07%
R&D9.78M4.86M15.45M41.62M56.51M81.21M167.46M216.10M244.65M282.00M272.53M224.78M151.48M37.45M
R&D as % of Total Revenue--------6887.67%1386.44%428.69%2622.01%117.48%31.00%
Interest Expense-00000011.79M10.78M9.71M373.00K5.29M4.62M3.79M
Interest Expense % of Total Revenue--------303.46%47.75%0.59%61.65%3.58%3.14%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.29M51.83M106.12M324.98M263.91M217.78M391.84M342.94M588.12M468.13M376.42M165.50M109.10M20.23M
Total Liabilities1.31M62.84M2.94M9.88M10.18M39.91M52.98M52.16M125.78M188.51M249.78M264.74M206.38M58.74M
Total Equity2.98M-11.02M103.18M315.10M253.74M177.86M338.86M290.78M462.34M279.61M126.64M-99.23M-97.28M-38.50M
Cash4.21M51.62M21.90M23.75M47.97M79.22M60.70M74.32M200.40M106.08M92.94M25.84M25.03M8.48M
Total Debt1.00M----500.00K738.00K15.72M15.03M28.27M71.70M57.87M43.83M52.80M
Net Debt-3.20M-51.62M-21.90M-23.75M-47.97M-79.22M-59.96M-58.60M-185.38M-77.81M-21.24M32.03M18.80M44.32M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.48M-5.97M-16.63M-37.16M-60.02M-87.50M-179.77M-235.63M-180.76M-220.52M-270.43M-192.98M-68.72M-50.94M
Investing Cash Flow-27.00K-3.00K-83.36M-220.13M83.74M98.71M-196.29M60.46M-120.73M22.26M202.96M123.87M8.62M18.15M
Financing Cash Flow15.12M53.38M70.27M259.23M506.00K20.05M357.54M188.79M427.57M103.94M53.08M2.01M59.28M16.10M
Capital Expenditure27.00K3.00K46.00K290.00K3.02M20.23M35.92M5.73M4.51M10.58M4.19M1.22M246.00K0
Free Cash Flow-2.50M-5.97M-16.67M-37.45M-63.05M-107.73M-215.70M-241.36M-185.27M-231.10M-274.62M-194.20M-68.96M-50.94M
Dividends Paid--0000-6.70M1.52M1.24M623.00K---
FCF to OCF101.09%100.05%100.28%100.78%105.03%123.12%119.98%102.43%102.50%104.80%101.55%100.63%100.36%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%--2.77%-0.82%-0.54%-0.23%---

Earnings

Report DateNov 12, 2014Feb 26, 2015May 7, 2015Aug 6, 2015Nov 5, 2015Mar 3, 2016May 5, 2016Aug 8, 2016Nov 4, 2016Mar 9, 2017May 4, 2017Aug 7, 2017Nov 9, 2017Feb 27, 2018May 8, 2018Aug 1, 2018Nov 6, 2018Feb 26, 2019May 9, 2019Aug 8, 2019Nov 7, 2019Feb 27, 2020May 6, 2020Aug 5, 2020Nov 9, 2020Mar 1, 2021May 4, 2021Aug 9, 2021Nov 4, 2021Feb 28, 2022May 5, 2022Aug 8, 2022Nov 8, 2022Feb 8, 2023May 8, 2023Aug 8, 2023Nov 1, 2023Mar 28, 2024May 9, 2024Aug 12, 2024Nov 12, 2024Mar 7, 2025May 15, 2025Aug 11, 2025Nov 12, 2025Mar 16, 2026May 13, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate-56.14-0.35-11.08-11.05-13.95-11.93-0.55-15.33-19.36-24.51-0.74-21.13-24.50-1.14-23.09-24.43-28.19-33.25-1.51-37.40-36.06-33.52-1.43-29.57-26.94-0.74-23.01-21.82-23.43-0.69-24.51-20.26-19.34-9.70-9.51-16.51-16.40-12.05-0.26-2.24-3.50-3.49-3.07-0.32-0.66-0.10-0.22-0.35-
EPS Actual-105.00-0.67-10.50-15.50-10.75-18.75-0.58-16.50-22.00-15.75-0.88-23.50-25.50-1.15-26.25-28.75-32.25-43.75-1.44-40.00-32.75-34.00-1.20-28.50-23.00-0.95-21.50-22.75-22.50-0.96-21.75-7.82-20.50-18.00-18.00-17.00-16.50-14.00-0.23-3.10-2.93-1.193.500.19-0.32-0.35-0.29-0.32-
Surprise-87.03%-91.43%5.23%-40.27%22.94%-57.17%-5.45%-7.63%-13.64%35.74%-18.92%-11.22%-4.08%-0.88%-13.69%-17.68%-14.40%-31.58%4.64%-6.95%9.18%-1.43%16.08%3.62%14.63%-28.38%6.56%-4.26%3.97%-39.13%11.26%61.40%-6.00%-85.57%-89.27%-2.97%-0.61%-16.18%11.54%-38.39%16.29%65.90%214.01%159.38%51.52%-250.00%-35.86%8.57%-
TimingPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours---

Key Statistics & Ratios

Market Cap85.72M
Enterprise Value85.93M
Trailing P/E0.00
Forward P/E16.16
PEG Ratio0.00
Price / Sales13.84
Price / Book16.14
EPS-1.54
Book Value-3.92
Revenue (TTM)6.19M
Gross Profit (TTM)4.66M
EBITDA-11.06M
Profit Margin-269.42%
Operating Margin-627.46%
Return on Equity-2014.86%
Return on Assets-24.14%
Shares Outstanding10.04M
Shares Float4.62M
Beta0.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 13.67
  • Strong Buy
    4
  • Hold
    1

Ownership Breakdown

Institutions
57.67%
Insiders
16.80%
Retail / Other
25.53%

Top Institutional Holders

  • EcoR1 Capital, LLC
    1.55M15.46%
  • Adage Capital Partners Gp LLC
    850.00K8.47%
  • Redmile Group, LLC
    441.70K4.40%
  • Mackenzie Investments
    313.62K3.12%
  • Vanguard Capital Management, LLC
    217.86K2.17%
  • Point72 Asset Management, L.P.
    194.26K1.94%
  • Acadian Asset Management LLC
    130.91K1.30%
  • BlackRock Inc
    79.02K0.79%
  • Geode Capital Management, LLC
    66.15K0.66%
  • UBS Group AG
    50.07K0.50%
  • Staley Capital Advisers Inc
    50.00K0.50%
  • Jane Street Group LLC
    33.87K0.34%
  • Vanguard Fiduciary Trust Co
    33.62K0.33%
  • Bridgeway Capital Management, LLC
    32.69K0.33%
  • State Street Corp
    26.45K0.26%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    158.65K1.58%
  • Mackenzie GQE US Small Cap F8
    66.98K0.67%
  • Fidelity Extended Market Index
    35.39K0.35%
  • iShares Micro-Cap ETF
    18.82K0.19%
  • Fidelity VIP Disciplined Small Cap Init
    16.24K0.16%

Stock Splits

  • Jun 20, 20241:25